Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society
Purpose: To report the results of the survey for the role of anti-VEGF in the management of retinopathy of prematurity (ROP) among the members of Indian ROP (iROP) society. Methods: A questionnaire was designed in English using Google forms and its link was circulated to the members of the iROP soci...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Indian Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=8;spage=2158;epage=2163;aulast=Gangwe |
id |
doaj-c727505bcf8c40dc955e7cb391eaa648 |
---|---|
record_format |
Article |
spelling |
doaj-c727505bcf8c40dc955e7cb391eaa6482021-08-09T09:54:34ZengWolters Kluwer Medknow PublicationsIndian Journal of Ophthalmology0301-47381998-36892021-01-016982158216310.4103/ijo.IJO_200_21Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity SocietyAnil GangweDeepanshu AgrawalAnand VinekarRaj V AzadSwapnil M ParchandDeepshikha AgrawalPurpose: To report the results of the survey for the role of anti-VEGF in the management of retinopathy of prematurity (ROP) among the members of Indian ROP (iROP) society. Methods: A questionnaire was designed in English using Google forms and its link was circulated to the members of the iROP society on their mobile numbers. The survey included questions pertaining to demographics, anti-VEGF agents, injection technique, post-injection follow-up, and documentation pertaining to their ROP practice. Anonymous responses were obtained and analyzed for individual questions. Results: 226 members of the society were contacted and 157 responded (69.4%) to the survey. 137 (87.2%) respondents used anti-VEGF in the management of ROP. Aggressive posterior ROP (APROP) was the most common indication (78, 52.7%). The procedure was carried out in the main operation room (102, 70.3%) simultaneously for both the eyes (97; 68%) under topical anesthesia (134; 86.4%) by most of the respondents. One-hundred thirteen (77.9%) respondents used half of the adult dose, irrespective of the agent used; however, more than half of them preferred bevacizumab (85, 54%). 53 (36.3%) respondents followed up infants as per disease severity rather than a fixed schedule while only 33 (23%) performed photo documentation. 151 (96.2%) respondents felt the need for guidelines regarding the usage of anti-VEGF in ROP. Conclusion: There is an increase in the trend towards the use of anti-VEGF in the management of severe ROP, particularly APROP. However, there are considerable variations among the ROP practitioners regarding the agent, dosage, follow-up schedule, and documentation, suggesting the need for uniform guidelines.http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=8;spage=2158;epage=2163;aulast=Gangweanti-vegfindiaretinopathy of prematuritysurvey |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anil Gangwe Deepanshu Agrawal Anand Vinekar Raj V Azad Swapnil M Parchand Deepshikha Agrawal |
spellingShingle |
Anil Gangwe Deepanshu Agrawal Anand Vinekar Raj V Azad Swapnil M Parchand Deepshikha Agrawal Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society Indian Journal of Ophthalmology anti-vegf india retinopathy of prematurity survey |
author_facet |
Anil Gangwe Deepanshu Agrawal Anand Vinekar Raj V Azad Swapnil M Parchand Deepshikha Agrawal |
author_sort |
Anil Gangwe |
title |
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society |
title_short |
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society |
title_full |
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society |
title_fullStr |
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society |
title_full_unstemmed |
Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society |
title_sort |
anti-vascular endothelial growth factor in the management of retinopathy of prematurity: a survey among the members of indian retinopathy of prematurity society |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Ophthalmology |
issn |
0301-4738 1998-3689 |
publishDate |
2021-01-01 |
description |
Purpose: To report the results of the survey for the role of anti-VEGF in the management of retinopathy of prematurity (ROP) among the members of Indian ROP (iROP) society. Methods: A questionnaire was designed in English using Google forms and its link was circulated to the members of the iROP society on their mobile numbers. The survey included questions pertaining to demographics, anti-VEGF agents, injection technique, post-injection follow-up, and documentation pertaining to their ROP practice. Anonymous responses were obtained and analyzed for individual questions. Results: 226 members of the society were contacted and 157 responded (69.4%) to the survey. 137 (87.2%) respondents used anti-VEGF in the management of ROP. Aggressive posterior ROP (APROP) was the most common indication (78, 52.7%). The procedure was carried out in the main operation room (102, 70.3%) simultaneously for both the eyes (97; 68%) under topical anesthesia (134; 86.4%) by most of the respondents. One-hundred thirteen (77.9%) respondents used half of the adult dose, irrespective of the agent used; however, more than half of them preferred bevacizumab (85, 54%). 53 (36.3%) respondents followed up infants as per disease severity rather than a fixed schedule while only 33 (23%) performed photo documentation. 151 (96.2%) respondents felt the need for guidelines regarding the usage of anti-VEGF in ROP. Conclusion: There is an increase in the trend towards the use of anti-VEGF in the management of severe ROP, particularly APROP. However, there are considerable variations among the ROP practitioners regarding the agent, dosage, follow-up schedule, and documentation, suggesting the need for uniform guidelines. |
topic |
anti-vegf india retinopathy of prematurity survey |
url |
http://www.ijo.in/article.asp?issn=0301-4738;year=2021;volume=69;issue=8;spage=2158;epage=2163;aulast=Gangwe |
work_keys_str_mv |
AT anilgangwe antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety AT deepanshuagrawal antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety AT anandvinekar antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety AT rajvazad antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety AT swapnilmparchand antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety AT deepshikhaagrawal antivascularendothelialgrowthfactorinthemanagementofretinopathyofprematurityasurveyamongthemembersofindianretinopathyofprematuritysociety |
_version_ |
1721214544473227264 |